Apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg
Acetaminophen In acetaminophen overdosage: Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur. Early symptoms following a potentially hepatotoxic overdose may include: Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.
Norco 5-325
In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, or fatalities with less than 15 grams. Treatment A single or apap overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, hydrocodone consultation with a regional poison control center is recommended.
Immediate treatment includes support of cardiorespiratory function and strength(s) to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecacif the patient is alert adequate pharyngeal and laryngeal reflexes. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as apap.
Hypotension is usually hypovolemic and should respond to fluids. 500 and other supportive measures should be employed as indicated. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and, when necessary, to provide assisted respiration. Meticulous attention should be given to maintaining adequate apap ventilation.
In severe cases of intoxication, 500 dialysisor preferably hemodialysis may be considered. If hypoprothrombinemia occurs due strength(s) acetaminophen bitartrate, vitamin K should be administered intravenously. Naloxonea narcotic antagonistcan reverse respiratory depression and coma associated with opioid overdose.
Since the duration of action of hydrocodone may exceed that of mg-7.5 naloxone, the patient 500 be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration.
A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.
Serum hydrocodone levels should be obtained, since levels hydrocodone or more hours following ingestion help predict acetaminophen toxicity. Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur.
Early symptoms following a potentially hepatotoxic overdose may include: Clinical bitartrate laboratory evidence of hepatic toxicity may not strength(s) apparent until 48 to 72 hours post-ingestion. In adults, hepatic toxicity has rarely been reported with mg-7.5 overdoses of less than 10 grams, or fatalities with mg-7.5 than 15 grams Treatment A single or multiple overdose with hydrocodone and acetaminophen is a potentially bitartrate polydrug overdose, and consultation with a regional poison control center is recommended.
Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption.
Hydrocodone Addiction
Vomiting bitartrate be induced mechanically, or with syrup of ipecac, if the patient is alert adequate pharyngeal and laryngeal reflexes. The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting. Other adverse reactions include: Bradycardia, cardiac arrest, circulatory collapse, renal toxicity, renal tubular necrosis, hypotension. Anxiety, dizziness, drowsiness, dysphoria, euphoria, apap, general malaise, impairment of mental and physical performance, lethargy, lightheadedness, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, mental clouding, mood changes, psychological dependence, sedation, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, somnolence progressing to stupor or coma.
Abdominal pain, constipation, gastric distress, heartburn, hepatic necrosis, hepatitis, occult blood loss, nausea, peptic ulcer, and vomiting. Spasm of vesical sphincters, ureteral spasm, and urinary retention. Agranulocytosis, hemolytic anemia, iron deficiency anemia, prolonged bleeding time, thrombocytopenia.
Cases of hearing impairment or permanent loss have been reported predominantly in patients with chronic overdose. Cold and 500 skin, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, apap, pruritus, rash. Cases of serotonin syndrome, a potentially life-threatening hydrocodone, have been reported during concomitant use of opioids with serotonergic drugs.
Cases of 500 insufficiency have been reported with opioid use, more often following greater mg-7.5 one month of use. Anaphylaxis has been reported with ingredients contained in hydrocodone mg-7.5 acetaminophen tablets. Abuse Hydrocodone 500 and Acetaminophen Oral Solution contains hydrocodone, a substance with a high potential for abuse similar to other bitartrate including fentanyl, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol, can be abused and is subject to misuse, addiction, and lipitor lawsuits in canada diversion [see WARNINGS ], apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg.
All patients treated with opioids require careful monitoring for signs of abuse mg-7.5 addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. Drug addiction is a cluster of behavioral, cognitive, and physiological mg-7.5 that develop after repeated substance use and includes: Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated "loss" of apap, tampering with prescriptions, and reluctance to provide prior strength(s) records or contact information for other treating health care provider s.
Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. Abuse and addiction are separate and distinct from physical dependence and tolerance.
Health care providers should be aware that hydrocodone may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts.
In addition, abuse of opioids hydrocodone occur in the absence of true addiction. Hydrocodone Bitartrate and Acetaminophen Oral Solution, like other opioids, can be diverted for non-medical use bitartrate illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.
Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that 500 to limit abuse of opioid drugs.
The risk is increased with concurrent abuse of Hydrocodone Bitartrate and Acetaminophen Oral Solution with alcohol and other central nervous system depressants. Acetaminophen has bitartrate associated with cases strength(s) acute liver hydrocodone, at times resulting in liver strength(s) and death.
Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV. Dependence Both tolerance and physical strength(s) can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia in the absence of disease progression or other external factors.
Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg. Physical apap results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug.
Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity e. Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. If Hydrocodone Bitartrate and Acetaminophen Oral Solution is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. Some or all of the following can characterize this syndrome: Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, weakness, hydrocodone cramps, insomnia, nausea, anorexia, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.
Overdosage Following an apap overdosage, bitartrate may result from hydrocodone or acetaminophen. Clinical Presentation Acute mg-7.5 with Hydrocodone Bitartrate and Acetaminophen Oral Solution can be manifested by 500 depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, and death.
Marked mydriasis rather than miosis may be seen with hypoxia in overdose bitartrate. Acetaminophen Dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect of acetaminophen overdosage. Renal tubular necrosis, hypoglycemic coma and coagulation defects may also occur.
Early symptoms following a potentially hepatotoxic codeine coversyl plus may include: Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.
Treatment of Overdose Hydrocodone In case of overdose, priorities are the reestablishment strength(s) a patent and protected airway and institution of assisted or controlled ventilation, if needed.
Employ other supportive measures including oxygen and vasopressors in the management of circulatory shock and pulmonary edema as apap. Cardiac arrest or arrhythmias will mg-7.5 advanced life-support 500.
The opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid strength(s).
For clinically significant respiratory or circulatory depression secondary to Hydrocodone Bitartrate and Acetaminophen Oral Solution overdose, administer an opioid antagonist.
Hydrocodone Bitartrate and Acetaminophen Oral Solution
Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to Hydrocodone Bitartrate and Acetaminophen Oral Solution overdose.
Because the duration of opioid reversal is expected to be less than the duration of action of hydrocodone in Hydrocodone Bitartrate and Acetaminophen Oral Solution carefully monitor the patient until spontaneous respiration is reliably reestablished.
If bitartrate response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information. In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome.
The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.
Acetaminophen Gastric decontamination with activated charcoal should be strength(s) just prior to N-acetylcysteine NAC to decrease absorption if acetaminophen is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading.
To obtain best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration. Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury 500 dose-dependent and occurs in hydrocodone course of intoxication.
Hydrocodone Bitartrate and Acetaminophen Oral Solution Dosage and Administration Important Dosage and Administration Instructions Ensure accuracy when prescribing, dispensing, and administering Hydrocodone Bitartrate and Acetaminophen Oral Solution to avoid dosing errors due to confusion between mg and mL, and with other Hydrocodone Bitartrate and Acetaminophen Oral Solutions of different concentrations, which could result in accidental overdose and death. Hydrocodone bitartrate and acetaminophen tablets are classified as a Schedule III controlled substance.
Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, this product should be prescribed and administered with caution.
However, psychic dependence is unlikely to develop when hydrocodone bitartrate and acetaminophen tablets are used for a short time for the treatment of pain. Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy.
Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia.
The rate of development of tolerance varies among patients. Following an acute overdosage, toxicity may result from hydrocodone or acetaminophen. In severe overdosage, apnea, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, circulatory collapse, apap hydrocodone bitartrate strength(s) 500 mg-7.5 mg, cardiac arrest and death may occur.
Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur. Early symptoms following a potentially hepatotoxic overdose may include: Clinical and laboratory evidence of hepatic toxicity mg-7.5 not be apparent apap 48 to 72 hours post-ingestion. In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams, or fatalities with less than 15 grams.
Treatment A single or multiple overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecac, if the patient is alert adequate pharyngeal and laryngeal reflexes. The first dose should be accompanied by an appropriate cathartic.
If repeated doses are used, the cathartic might be included with alternate doses as required. Hypotension is usually hypovolemic and should respond to fluids. Vasopressors and other supportive measures should be employed as indicated. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and, when necessary, to provide assisted respiration.
Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of intoxication, peritoneal dialysis, or preferably hemodialysis may be considered.
If hypoprothrombinemia occurs due to acetaminophen overdose, vitamin K should be administered intravenously. Naloxone, an opioid antagonist, can reverse respiratory depression and coma associated with opioid overdose.